Drug Trial Radar · NCT02065869
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Last checked: Nov 19, 2026Latest source record: Sep 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
187
Actual
Start
Apr 2014
Primary completion
Jun 2020
Study completion Sep 7, 2021
Sponsor
- Lead sponsor
- Bellicum PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 19, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 month, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially matched family donor. The study will assess whether immune cells, called T cells, from the family donor, that are specially grown in the laboratory and given back to the patient along with the stem cell transplant can help the immune system recover faster after transplant. As a safety measure these T cells have been programmed with a self-destruct switch so that they can be destroyed if they start to react against tissues (Graft versus host disease).
Conditions
- Acute Lymphoblastic Leukemia
- Leukemia, Acute Myeloid (AML), Child
- Lymphoma, Non-Hodgkin
- Myelodysplastic Syndrome
- Primary Immunodeficiency
- Anemia, Aplastic
- Osteopetrosis
- Hemoglobinopathies
- Cytopenia
- Fanconi Anemia
- Diamond Blackfan Anemia
- Thalassemia
- Anemia, Sickle Cell
Interventions
BPX-501 T cellsBiological
1x10E6 cells/kg infused on Day 0
RimiducidDrug
0.4mg/kg administered IV to treat GVHD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free Survival (EFS) at 180 Days After TransplantTime frame: 180 days after transplant
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
IRCCS Ospedale Pediatrico Bambino Gesù
Roma, Italy
Royal Free London NHS Foundation Trust
London, United Kingdom
Institute of Child Health & Great Ormond Street Hospital
London, United Kingdom
Great North Children's Hospital
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.